Because of WNT7B’s aggressive role in HBV-mediated hepatocarcinogenesis and L-HBs-mediated sorafenib resistance, it is appealing and effective for improving drug resistance in HBV-induced HCC. Here, WNT7B is linked to hepatocellular carcinoma.